 Destiny Pharmas 29021 year-end cash of 4.65mln together with a 6.5mln fundraise in March 2022 provides a funding runway into mid-2023, says house broker finnCap. With several companies active in the NTCD-M3 data room, we look forward to the company securing a partner to co-fund the Phase 3 trial. 